RNS Number : 1439J
ValiRx PLC
14 August 2023

ValiRx PLC

("ValiRx" or the "Company")

Collaborative Services Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that the CompanyÕs wholly owned subsidiary, Inaphaea BioLabs Limited ("Inaphaea"), has entered into a collaborative services agreement with Agility Life Sciences Limited ("Agility") ("Collaborative Services Agreement").

The Collaborative Services Agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) and Agility's capabilities for formulation development and optimisation, pre-formulation studies and analysis.

Under the agreement, service users of Inaphaea will be able to benefit from Agility's capabilities in a single service contract with Inaphaea and similarly, service users of Agility will be able to access Inaphaea's capabilities through their service contract with Agility. This will enable a coherent, single point of contact for service users to formulate and test their drug candidates.

Dr Suzy Dilly, CEO at ValiRx explains "We have appreciated the skills and creativity displayed by Agility during the two projects we have run with them, so we're delighted to be able to offer these capabilities to our service users, as well as to continue using these capabilities for our in-house programmes.

"In a comparative manner to our collaborative services agreement with Physiomics announced in April 2023, this new arrangement with Agility further expands the Inaphaea service capability. This agreement is very much reciprocal, and we expect to be able to offer our services to Agility customers just as much as offering their services to ours."

Professor Claire Thompson, CEO at Agility commented "We are really excited about entering into this Collaborative Service Agreement with Inaphaea. This will enable our clients to take the next steps in their development programmes by testing their prototype formulations in the Inaphaea cell based studies. We believe this will be beneficial to both companies as well as to our clients, creating a more comprehensive scientific environment, and accelerating development timelines."

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO **Inaphaea BioLabs Limited** Dr Andrew Carnegie, Head of Strategic Commercial Development	**Tel: +44 (0) 2476 796496** **www.valirx.com** Suzanne.Dilly@valirx.com **www.inaphaea.com** Andrew.Carnegie@inaphaea.com
V Formation (Public Relations) Lucy Wharton Ð Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** **www.vformation.biz** lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Cenkos Securities plc (Joint Broker)	**Tel: +44 (0) 20 7397 8900**

Dale Bellis/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	**Tel: +44 (0) 20 3657 0050**

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and womenÕs health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRxÕs portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

About Agility Life Sciences

Agility Life Sciences is an award-winning CDMO, accelerating your milestones and futureproofing your products. Agility turns badly behaved molecules into smart formulations which give them the best chance of success in preclinical studies, and enable them to be accelerated to clinic.

Their core expertise is in developing formulations for small molecules and peptides for various routes of administration including oral, ocular, IV, intranasal and topical.

The ÒFast Futureproof FormulationsÓ approach always starts with an end in mind, developing products which enable molecules to be accelerated from discovery to clinic. Developing and manufacturing formulations to meet the needs of their clients includes:

¥ Overcoming solubility and permeability issues.

¥ Immediate, controlled and sustained release.

¥ Formulations and analytical methods suitable for preclinical safety and efficacy studies, including GLP tox studies.

¥ Clinical and commercial prototypes.

¥ Reverse engineering of existing products.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of

this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRNKNBPPBKDOFD